What are your top takeaways in Breast Cancer from ASTRO 2024?
There were a number of important presentations on breast cancer at the ASTRO 2024 meeting. The three randomized trial discussed below stood out.
Hypofractionated radiotherapy should be considered the standard of care for most patients with breast cancer, regardless of surgical approach or treatment volumes.
(PL 01 – Plenary Session) 1 - A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Recons...
RT CHARM: Dr. @Dr. First Last's presentation regarding the RT CHARM trial of conventional fraction PMRT vs moderately hypofractionated PMRT revealed that hypofractionated PMRT is safe, effective, and non-inferior to conventional fractionation among patients who undergo reconstruction. This large, ra...
From the Plenary Session Monday 1:30 pm: A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505) presented by Dr. @Dr. First Last. I have been slow on the uptake with moderate hypofractionation in the post-maste...